Hosted on MSN1d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
Hosted on MSN4d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
Daily4d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
The Pharma Letter4d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
Pharmabiz4d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
pharmaphorum12d
GSK's Nucala gains US use in rare autoimmune disease
GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...
GSK's Nucala gets third approval in China
GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...
Nasdaq5d
GSK’s Nucala Gains Approval in China for CRSwNP
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...